Adaptimmune Announces Delisting from Nasdaq
Adaptimmune (NASDAQ: ADAP) announced its Board has authorized voluntary delisting of its ADSs from Nasdaq and deregistration under Section 12(b) of the Exchange Act, with a Form 25 expected to be filed on or about October 28, 2025. Trading on Nasdaq is expected to be suspended following the close of trading on or about October 27, 2025. The company expects deregistration to become effective approximately 90 days after the Form 25 filing and intends to file a Form 15 if it has fewer than 300 shareholders of record, which would suspend Exchange Act reporting obligations.
The Board said the move follows the July 31, 2025 transaction with US WorldMeds and aims to reduce costs from SEC reporting, Sarbanes-Oxley compliance, and Nasdaq listing requirements. The company expects its ADSs may be quoted on the OTC Pink market but warned there is no guarantee a broker will continue to make a market.
Adaptimmune (NASDAQ: ADAP) ha annunciato che il suo Consiglio ha autorizzato la quotazione volontaria delle sue ADSs dal Nasdaq e la deregistrazione ai sensi della Sezione 12(b) del Exchange Act, con un modulo 25 previsto da presentare intorno al 28 ottobre 2025. Si prevede che la negoziazione sul Nasdaq sia sospesa dopo la chiusura delle contrattazioni intorno al 27 ottobre 2025. L'azienda prevede che la deregistrazione diventi efficace circa 90 giorni dopo la presentazione del modulo 25 e intende presentare un modulo 15 se ha meno di 300 azionisti registrati, il che sospenderà gli obblighi di reporting ai sensi del Exchange Act.
Il Consiglio ha detto che la mossa segue la transazione del 31 luglio 2025 con US WorldMeds e mira a ridurre i costi legati alla segnalazione SEC, alla conformità a Sarbanes-Oxley e ai requisiti di quotazione Nasdaq. L'azienda prevede che i suoi ADS possano essere quotati sul mercato OTC Pink, ma avverte che non vi è alcuna garanzia che un broker continuerà a fare mercato.
Adaptimmune (NASDAQ: ADAP) anunció que su Junta ha autorizado el desliste voluntario de sus ADS en Nasdaq y la deregistración conforme a la Sección 12(b) de la Exchange Act, previéndose presentar un Formulario 25 alrededor del 28 de octubre de 2025. Se espera que la negociación en Nasdaq se suspenda tras el cierre de operaciones alrededor del 27 de octubre de 2025. La compañía espera que la deregistración entre en vigor aproximadamente 90 días después de la presentación del Formulario 25 y tiene la intención de presentar un Formulario 15 si tiene menos de 300 accionistas registrados, lo que suspendería las obligaciones de reporte conforme a la Exchange Act.
La Junta indicó que la medida sigue a la transacción del 31 de julio de 2025 con US WorldMeds y tiene como objetivo reducir costos de reporte ante la SEC, cumplimiento de Sarbanes-Oxley y requisitos de cotización en Nasdaq. La compañía espera que sus ADS puedan cotizar en el mercado OTC Pink, pero advirtió que no hay garantía de que un corredor siga haciendo un mercado.
Adaptimmune (NASDAQ: ADAP)는 이사회가 Nasdaq에서의 ADS 상장 자발적 상장폐지와 Exchange Act 섹션 12(b)에 따른 등록해지 권한을 승인했으며, 2025년 10월 28일 경에 Form 25를 제출할 예정이라고 발표했습니다. Nasdaq에서의 거래는 대략 2025년 10월 27일 경 종가 후에 중단될 것으로 예상됩니다. 이 등록해지는 Form 25 제출 후 대략 90일 정도에 시행될 것이며, 보유 주주가 300주 이하의 등록 주주인 경우 Form 15를 제출하여 Exchange Act 보고 의무를 중단할 계획이라고 합니다.
이사회는 이 조치가 2025년 7월 31일 US WorldMeds와의 거래를 따른 것이며 SEC 보고, Sarbanes-Oxley 준수, Nasdaq 상장 요건으로 인한 비용 절감을 목표로 한다고 밝혔습니다. 이 회사는 ADS가 OTC Pink 시장에 계속 인용될 수 있을 수 있지만, 브로커가 시장을 계속 형성할 보장은 없다고 경고했습니다.
Adaptimmune (NASDAQ: ADAP) a annoncé que son conseil d'administration a autorisé le retrait volontaire des ADS du Nasdaq et la deregistration en vertu de l'article 12(b) de la Exchange Act, avec un Formulaire 25 prévu pour être déposé vers le 28 octobre 2025. La négociation sur le Nasdaq devrait être suspendue après la clôture des échanges vers le 27 octobre 2025. L'entreprise prévoit que la deregistration devienne effective environ 90 jours après le dépôt du Formulaire 25 et a l'intention de déposer un Formulaire 15 si elle compte moins de 300 actionnaires inscrits, ce qui suspendrait les obligations de reporting en vertu de la Exchange Act.
Le conseil a déclaré que la démarche suit la transaction du 31 juillet 2025 avec US WorldMeds et vise à réduire les coûts de reporting auprès de la SEC, à la conformité Sarbanes-Oxley et aux exigences de cotation Nasdaq. L'entreprise s'attend à ce que ses ADS puissent être cités sur le marché OTC Pink, mais a averti qu'il n'y a aucune garantie qu'un courtier continue à faire marché.
Adaptimmune (NASDAQ: ADAP) gab bekannt, dass ihr Vorstand den freiwilligen Delisting ihrer ADSs von Nasdaq und die Deregulierung gemäß Abschnitt 12(b) des Exchange Act genehmigt hat, wobei erwartet wird, dass am oder um den 28. Oktober 2025 ein Form 25 eingereicht wird. Der Handel an der Nasdaq soll nach dem Handelsschluss am oder um den 27. Oktober 2025 ausgesetzt werden. Das Unternehmen erwartet, dass die Deregistrierung ungefähr 90 Tage nach der Einreichung des Form 25 wirksam wird und beabsichtigt, ein Form 15 einzureichen, falls es weniger als 300 Aktionäre des Inhaberregisters hat, was die Berichtspflichten gemäß dem Exchange Act aussetzen würde.
Der Vorstand sagte, der Schritt folge der Transaktion vom 31. Juli 2025 mit US WorldMeds und zielt darauf ab, Kosten durch SEC-Berichterstattung, Sarbanes-Oxley-Compliance und Nasdaq-Listing-Anforderungen zu senken. Das Unternehmen erwartet, dass seine ADSs möglicherweise auf dem OTC Pink-Markt gehandelt werden, warnte jedoch, dass es keine Garantie dafür gebe, dass ein Broker weiterhin einen Markt bildet.
Adaptimmune (ناسداك: ADAP) أعلنت أن مجلس إدارتها قد فوّض بالإدراج الطوعي لأسهم ADSs الخاصة بها من ناسداك وإلغاء التسجيل وفقاً للمادة 12(b) من قانون التبادل، ومن المتوقع تقديم النموذج 25 في أو نحو 28 أكتوبر 2025. من المتوقع أن يتم تعليق التداول في ناسداك بعد إغلاق التداول في نحو 27 أكتوبر 2025. وتتوقع الشركة أن تصبح Deregistration سارية المفعول تقريباً بعد 90 يوماً من تقديم النموذج 25 وتعتزم تقديم النموذج 15 إذا كان لديها أقل من 300 حامل أسهم مسجل، وهو ما سيعلق التزامات الإبلاغ وفقاً لقانون التبادل.
قال المجلس إن هذه الخطوة تلت صفقة 31 يوليو 2025 مع US WorldMeds وتهدف إلى تقليل التكاليف المرتبطة بالإبلاغ لدى SEC والامتثال لـ Sarbanes-Oxley ومتطلبات الإدراج في Nasdaq. وتتوقع الشركة أن يتم إدراج ADSs الخاصة بها ربما في سوق OTC Pink لكنها حذرت من أنه لا يوجد ضمان بأن يواصل وسيط السوق إنشاء سوق.
Adaptimmune (NASDAQ: ADAP) 公布，其董事会已授权有条件地将其 ADS 从纳斯达克退市并根据交易法第12(b)条进行退市登记，预计在大约 2025年10月28日 提交 Form 25。预计在大约 2025年10月27日 收盘后暂停在纳斯达克的交易。该公司预计在提交 Form 25 约 90天 后生效 deregistration，并打算在少于 300 名登记股东 时提交 Form 15，从而暂停根据交易法的披露义务。
董事会表示，此举是在 2025 年 7 月 31 日与 US WorldMeds 的交易之后作出的，旨在降低证券交易委员会（SEC）披露、萨班斯-奥克斯利法合规及纳斯达克上市要求所产生的成本。公司预计其 ADS 可能在 OTC Pink 市场报价，但警告称并不保证经纪商会继续做市。
- Form 25 filing expected on or about Oct 28, 2025
- Trading suspension targeted after close on Oct 27, 2025
- Deregistration expected ~90 days after Form 25 filing
- Company intends to file Form 15 if fewer than 300 shareholders, suspending reporting
- Loss of Nasdaq listing, ending access to major exchange liquidity
- ADS trading may move to OTC Pink, reducing visibility and liquidity
- No guarantee a broker will make a market, risking limited tradability
- Suspension of SEC reporting could reduce transparency for investors
Insights
Adaptimmune will voluntarily delist and deregister ADSs to cut public‑reporting costs after its July 31, 2025 transaction.
The Board of Adaptimmune decided to file Form 25 and voluntarily delist its ADSs from Nasdaq, expecting trading suspension on or about
Key dependencies and risks are explicit in the disclosure. The company already had a Nasdaq bid‑price exception through
Watch the following near‑term items: confirmation of the Form 25 filing date around
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determined to initiate the delisting of its American Depositary Shares ("ADSs"), each representing six ordinary shares, from The Nasdaq Capital Market ("Nasdaq") and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "As we noted previously, the transaction with USWM CT, LLC, a subsidiary of US WorldMeds Partners, LLC (collectively, "US WorldMeds") followed an extensive review of strategic alternatives and represented the best path forward for Adaptimmune, our patients and other stakeholders. Since closing the transaction on July 31, 2025, we have been restructuring to support the assets transferred to US WorldMeds, and have continued our efforts to maximize value from our remaining assets including programs targeting PRAME and CD70. The delisting from Nasdaq and deregistration should facilitate cost reductions and further support our goal to maximize value going forward."
As previously reported by the Company, the Company received a written notice on September 22, 2025, from the Nasdaq Hearings Panel (the "Panel") confirming that the Company had been granted an exception period to regain compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of
On October 16, 2025, the Company notified The Nasdaq Stock Market, LLC, pursuant to authorization by the Board on October 15, 2025, that it intends to file a Form 25 with the U.S. Securities and Exchange Commission (the "SEC") on or about October 28, 2025 to effect the voluntary delisting of the Company's ADSs from Nasdaq and to deregister the ADSs under Section 12(b) of the Exchange Act. Following confirmation by The Nasdaq Stock Market, LLC on October 17, 2025, the Company currently expects that the trading of its ADSs on Nasdaq will be suspended following the closing of trading on Nasdaq on or about October 27, 2025.
Following the delisting, any trading in the Company's ADSs would only occur in privately negotiated sales and potentially on an over-the-counter market. The Company currently expects that its ADSs will be quoted on the OTC Pink Limited Market, a market operated by OTC Markets Group Inc. (an "OTC market"), so that a trading market may continue to exist for its ADSs. There is no guarantee, however, that a broker will continue to make a market in the ADSs and that trading of the ADSs will continue on an OTC market or otherwise.
Ninety days after the date of filing of the Form 25, the deregistration of the Company's ADSs under Section 12(b) of the Exchange Act is expected to become effective. Following the delisting of the Company's ADSs from Nasdaq, the Company intends to file a Form 15 with the SEC certifying that it has fewer than 300 shareholders of record, upon which the Company's filing obligations under the Exchange Act will immediately be suspended, including the obligations to file all periodic reports.
The Board believes that the decision to delist the ADSs from Nasdaq and deregister and suspend the Company's reporting obligations under the Exchange Act is in the best interests of the Company and the holders of its ordinary shares and ADSs. As the Company continues with its efforts to maximize value from its remaining assets, the Board has determined that the burdens associated with operating as a registered public company listed on Nasdaq outweigh any advantages to the Company and the holders of its ordinary shares and ADSs. The Board's decision was based on careful review of numerous factors, including the potential for eliminating the significant costs associated with preparing and filing periodic reports with the SEC and the legal, audit and other expenses associated with being a public reporting company listed on Nasdaq, as well as the substantial costs and demands on management's time under the Sarbanes-Oxley Act of 2002, SEC rules and Nasdaq listing standards.
About Adaptimmune
We are a biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. In August 2024, the U.S. Food and Drug Administration ("FDA") approved our first biologics license application ("BLA") for TECELRA® (afamitresgene autoleucel) ("TECELRA"), which is the first engineered T-cell therapy for the treatment of a solid tumor cancer approved in the U.S. In July 2025, TECELRA was acquired by US WorldMeds alongside letetresgene autoleucel ("lete-cel"), for people with synovial sarcoma and myxoid liposarcoma, in relation to which a commercial launch was planned for 2026. A third clinical candidate, uza-cel, and the collaboration with Galapagos related to that cell therapy was also assigned to US Worldmeds as part of the transaction. We are working to ensure a smooth transition of TECELRA, lete-cel and uza-cel to US WorldMeds. We have also developed certain pre-clinical assets including our PRAME directed T-cell therapy and our CD-70 directed TRuC therapy. We are looking for strategic options in relation to these assets.
Forward-Looking Statements
This release contains "forward-looking statements" within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Exchange Act. Forward-looking statements address our expected future business, financial performance, financial condition, as well as the results of operations and often contain words such as "anticipate" "believe," "expect," "may," "plan," "potential," "will," and similar expressions. Such statements are based only upon current expectations of Adaptimmune. Reliance should not be placed on these forward-looking statements because they involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: risks associated with, and the timing and effectiveness of, the Company's voluntary delisting from Nasdaq; the Company's plans with respect to the delisting and deregistration of its ADSs; uncertainties regarding eligibility for and timing of quotation on an OTC market; and the trading of the Company's ADSs following the voluntary delisting of the ADSs from Nasdaq. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the year ended December 31, 2024, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.
Adaptimmune Contact
Investor Relations and Media Relations
Adrian Rawcliffe, Chief Executive Officer
Adrian.Rawcliffe@adaptimmune.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271003
FAQ
When will Adaptimmune (ADAP) be suspended from Nasdaq trading?
What filing will Adaptimmune (ADAP) make to delist from Nasdaq and when?
Will Adaptimmune (ADAP) continue reporting to the SEC after delisting?
Where will Adaptimmune (ADAP) ADSs trade after Nasdaq delisting?
Why did Adaptimmune (ADAP) decide to delist from Nasdaq?
How might the delisting affect ADAP shareholders' liquidity?
